The company’s latest innovation in the mental health realm is a long-acting version of olanzapine, an aging schizophrenia treatment that Eli Lilly markets as Zyprexa. More: Teva looks to peel back the onion on CNS, mental health conditions as it
read moreWhile the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts of the new class of cardiometabolic medicines have been consistently hamstrung by manufacturing and supply constraints.
read moreThe company already moved to cut its entire commercial sales force following several FDA setbacks in its efforts to introduce sotagliflozin in diabetes. More: FDA digs in its heels with another rejection for Lexicon's diabetes prospect Zynquista Source: fierce
read moreBristol Myers Squibb has reported positive results for two phase 3 trials of Sotyktu in adult patients who have psoriatic arthritis. Without revealing figures, BMS said that the POETYK PsA-1 and POETYK PsA-2 studies achieved their respective primary endpoints, as
read moreThe FDA approved Novo Nordisk’s tissue factor pathway inhibitor (TFPI) antagonist concizumab as a once-a-day treatment to prevent or curb the frequency of bleeding episodes in patients ages 12 and older who have hemophilia A or B with inhibitors. The
read moreViatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 products that are produced at the site from being imported into the U.S. for distribution. More: Viatris says India plant
read more© 1994 - 2025 B.M. Pharmaceuticals